POIESIS Clinical Trial: Latest Updates with Dr. Vachhani

New research developments in myelofibrosis that may open therapeutic opportunities and provide relevant information for patients and families.

Myelofibrosis is a chronic myeloproliferative neoplasm that can cause persistent symptoms such as severe fatigue, enlarged spleen, night sweats, weight loss, or difficulty maintaining a normal daily routine. In recent years, JAK inhibitors have represented an important advance in symptom control and quality of life improvement. However, not everyone responds in the same way or for the same duration.

In this context, clinical research continues to explore new strategies that may complement current treatments and offer alternatives for those who need additional options.

One of the most relevant studies in this field is the POIESIS clinical trial, led by Prof. Serge Verstovsek, and with the participation of Dr Pankit J. Vechhani, an reference in myelofibrosis, in this clinical trial. He will talk about next clinical trials for MPN.

The POIESIS study is evaluating a combination therapy for patients with myelofibrosis who are already receiving treatment with ruxolitinib, a widely used JAK inhibitor.

The research analyzes the combination of ruxolitinib with an investigational drug called navtemadlin, an MDM2 inhibitor. This mechanism aims to reactivate the p53 protein, which plays a key role in regulating cell growth.

The main objective of the study is to assess whether this combination can:

• Improve spleen size reduction

• Contribute to deeper disease control

• Provide additional benefit in patients who have had a suboptimal response to standard treatment

Beyond scientific data, studies like this have a direct impact on the daily lives of people living with myelofibrosis.

When symptoms persist or return, treatment decisions can generate uncertainty. New research pathways make it possible to:

• Expand available treatment options

• Encourage informed discussions with the medical team

• Consider participation in clinical trials when appropriate

• Better understand the course of the disease

Prof. Verstovsek has emphasized the importance of continuing to investigate combination therapies that not only control symptoms but also target the biological mechanisms of the disease.

POIESIS is a clinical trial in advanced phases of research. Preliminary results have shown promising signals in certain patient profiles, although it is essential to wait for full data to confirm efficacy and safety.

As with any clinical trial, participation follows strict criteria and involves specialized medical monitoring. Not everyone is eligible, and each case must be assessed individually.

Reliable information is a key tool in decision making. Understanding what a clinical trial is, how it works, and what participation involves allows patients to take an active role in their own process.

Within our community, we promote:

• Access to updated and validated information

• Spaces for dialogue between patients and specialists

• Resources to help track symptoms and disease evolution

Tools such as MPN Journal can support symptom tracking and enhance medical conversations. In addition, platforms like MPN World offer a secure space to share experiences with others facing similar situations, always with respect and confidentiality.

If you are living with myelofibrosis and would like to:

• Learn more details about the POIESIS trial

• Understand whether you might be eligible for a clinical trial

• Prepare questions for your next medical appointment

• Watch the full webinar with Prof. Serge Verstovsek

We invite you to explore the resources available on our website and to become part of our community.

Staying informed does not mean anticipating outcomes, but having the tools to make clearer decisions.

Research continues to move forward, and accompanying this progress with understandable information and community support is essential to improving the experience of those living with a myeloproliferative neoplasm.

We will continue sharing relevant updates on POIESIS and other advances that may provide real value to patients and families.

Register now!!